NEWARK, Del.--(BUSINESS WIRE)--QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is reinforcing its focus on qualitative and quantitative bioanalysis of biotherapeutics in Europe.

新泽西州纽瓦克（商业新闻短讯）--QPS Holdings，LLC（QPS）是一家全球合同研究组织（CRO），提供发现，临床前，生物分析，临床试验和临床研究服务，正在加强其对欧洲生物治疗药物定性和定量生物分析的关注。

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands. As part of this expansion, QPS has hired Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, to lead the newly expanded biotherapeutics and biomarkers Liquid Chromatography–Mass Spectrometry (LC-MS) quantitation team in the QPS laboratory in The Netherlands..

QPS宣布扩大和升级质谱仪队伍，并在荷兰格罗宁根增加了新的TripleTOF®6600+用于GLP定量。作为这一扩展的一部分，QPS聘请了生物分析高级主管丹尼尔·舒尔茨·詹德（DanielSchulz Jander）理学硕士、博士，领导荷兰QPS实验室新扩展的生物治疗学和生物标志物液相色谱-质谱（LC-MS）定量团队。。

This Sciex quadrupole time-of-flight high-resolution mass spectrometer is dedicated to GLP/GCP quantitation of oligonucleotide therapeutics and the planned expansion into oligonucleotide metabolite identification in Groningen, The Netherlands.

该Sciex四极杆飞行时间高分辨率质谱仪致力于寡核苷酸治疗剂的GLP/GCP定量，并计划在荷兰格罗宁根扩展到寡核苷酸代谢物鉴定。

“QPS is committed to responding to the needs of our clients in Europe by adding an Ultra High-Performance Liquid Chromatography–High-Resolution Mass Spectrometry (UPLC-HRMS) system in the Netherlands to focus on oligonucleotides. This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC..

“QPS致力于通过在荷兰增加超高效液相色谱-高分辨率质谱（UPLC-HRMS）系统来满足欧洲客户的需求，以专注于寡核苷酸。这是我们在美国特拉华州纽瓦克的工厂使用LC-（HR）MS/MS支持寡核苷酸药物开发20多年的自然延伸，”Zamas Lam说，博士，QPS LLC生物分析（质谱）和临床前开发全球负责人。。

“This increase in capacity and capability comes at a pivotal moment for QPS, as we continue our two-decades-long global effort to support the pharma and biotech industries in developing cutting-edge new therapies to address critical needs in healthcare worldwide. This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands..

“能力和能力的提高正值QPS的关键时刻，我们将继续我们长达二十年的全球努力，支持制药和生物技术行业开发尖端新疗法，以满足全球医疗保健的关键需求。随着核酸治疗和蛋白质药物开发工作的激增，这已成为更高的优先事项opment arena，”荷兰QPS生物分析高级主任，理学硕士，博士DanielSchulz-Jander说道。。

Daniel received his Dipl. Chem. from the University of Kassel in chemistry, his Doctor rerum naturalium from the Technische Universität München in environmental chemistry, followed by a post-doctoral fellowship in pesticide metabolism at UC Berkeley. Since then, Daniel’s scientific passion has been in bioanalysis.

丹尼尔收到了他的Dipl。化学。来自卡塞尔大学化学系，他的博士rerum naturalium来自慕尼黑工业大学环境化学系，随后在加州大学伯克利分校获得农药代谢博士后奖学金。从那时起，丹尼尔的科学热情一直在生物分析领域。

Starting in biotech at Ligand and Arena Pharmaceuticals, he moved to Medtronic where he built a bioanalytical team specializing in drug in tissue analyses. Since February 2022, Daniel has been the Senior Director of bioanalysis mass spectrometry at QPS Netherlands, where his team supports small and large molecule bioanalysis with LC-MS/MS as well as ICP/MS.

从Ligand and Arena Pharmaceuticals的生物技术开始，他搬到了美敦力，在那里他建立了一个专门从事组织药物分析的生物分析团队。自2022年2月以来，Daniel一直担任QPS Netherlands的生物分析质谱高级主管，他的团队支持LC-MS/MS和ICP/MS进行小分子和大分子生物分析。

With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development. This group’s expertise lies in the quantitation of oligonucleotides, peptides, intact proteins, and highly hydrophilic low-molecular-weight metabolite biomarkers by UPLC-HRMS, or by immunoaffinity UPLC-MS/MS (tandem mass spectrometry), or by hybridization-LC-fluorescence..

随着规模的扩大，该小组现在拥有PK/PD生物分析所需的所有LC-MS和其他色谱技术，以支持客户进行药物发现和基因疗法开发以及蛋白质药物开发。该小组的专业知识在于通过UPLC-HRMS，或通过免疫亲和UPLC-MS/MS（串联质谱）或通过杂交LC荧光定量寡核苷酸，肽，完整蛋白质和高亲水性低分子量代谢物生物标志物。。

ABOUT QPS HOLDINGS, LLC

关于QPS HOLDINGS，LLC

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe, India and Asia.

QPS是一家符合GLP/GCP的合同研究组织（CRO），提供最高级别的发现，临床前和临床药物开发服务。自1995年以来，它迅速从一家小型生物分析店扩展到一家全方位的CRO，在美国、欧洲、印度和亚洲拥有1200多名员工。

Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers.

今天，它提供扩展的药物合同研发服务，拥有神经药理学，DMPK，毒理学，生物分析，转化医学和临床开发方面的特殊专业知识。通过不断增强能力和资源，QPS坚定地致力于为其尊贵的客户提供优质、熟练的性能和值得信赖的服务。

For more information, visit www.qps.com or email info@qps.com..

有关更多信息，请访问www.qps.com或发送电子邮件info@qps.com..